The first daily GLP-1 pill for weight loss, oral semaglutide, marketed as Wegovy, was launched in the US last year, expanding access to obesity treatment beyond injections.

For some reason, YouTube is convinced that my husband is a fat Latino. Apparently, watching hours-long videos of classical music, the occasional pickleball championship, and indulging in a daily dose ...

Since 2023, Eli Lilly and Co. has filed lawsuits against dozens of compound pharmacies, weight-loss centers and health spas that produced and sold copies of Mounjaro and Zepbound.

Vivtex Corporation, launched in 2018 as a spinoff of the Massachusetts Institute of Technology (MIT), will license oral drug-delivery technologies to Novo for weight loss, diabetes, and related ...

The Danish drugmaker is collaborating with Vivtex, cofounded by billionaire Robert Langer, to quickly iterate oral versions ...

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures ...

Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion to develop ...

The healthcare company said all doses will shift to a single monthly list price, cutting Wegovy’s price by about 50% and ...

President Trump has a tricky line to walk tonight during the first State of the Union address of his second term. This is his ...

Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday. Ciara Lee reports.

The Danish drugmaker said it plans to offer the medicines for $675 per month starting in January 2027, representing a 50% reduction in price for Wegovy and a 35% reduction for Ozempic. Novo Nordisk ...

Novo Nordisk stock fell over 16% Monday after it said its next-generation weight loss drug didn't meet its primary target.